Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii

Implications for the target of macrolide antibiotics

Con J M Beckers, David S. Roos, Robert G K Donald, Benjamin J. Luft, J. Conrad Schwab, Yang Cao, Keith A Joiner

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

We investigated potential targets for the activity of protein synthesis inhibitors against the protozoan parasite Toxoplasma gondii. Although nanomolar concentrations of azithromycin and clindamycin prevent replication of T. gondii in both cell culture and in vivo assays, no inhibition of protein labeling was observed in either extracellular or intracellular parasites treated with up to 100 μM drug for up to 24 h. Quantitative analysis of > 300 individual spots on two-dimensional gels revealed no proteins selectively depleted by 100 μM azithromycin. In contrast, cycloheximide inhibited protein synthesis in a dose-dependent manner. Nucleotide sequence analysis of the peptidyl transferase region from genes encoding the large subunit of the parasite's ribosomal RNA predict that the cytoplasmic ribosomes of T. gondii, like other eukaryotic ribosomes, should be resistant to macrolide antibiotics. Combining cycloheximide treatment with two-dimensional gel analysis revealed a small subset of parasite proteins likely to be synthesized on mitochondrial ribosomes. Synthesis of these proteins was inhibited by 100 μM tetracycline, but not by 100 μM azithromycin or clindamycin. Ribosomal DNA sequences believed to be derived from the T. gondii mitochondrial genome predict macrolide/lincosamide resistance. PCR amplification of total T. gondii DNA identified an additional class of prokaryotic-type ribosomal genes, similar to the plastid-like ribosomal genes of the Plasmodium falciparum. Ribosomes encoded by these genes are predicted to be sensitive to the lincosamide/macrolide class of antibiotics, and may serve as the functional target for azithromycin, clindamycin, and other protein synthesis inhibitors in Toxoplasma and related parasites.

Original languageEnglish (US)
Pages (from-to)367-376
Number of pages10
JournalJournal of Clinical Investigation
Volume95
Issue number1
StatePublished - Jan 1995
Externally publishedYes

Fingerprint

Macrolides
Toxoplasma
Azithromycin
Parasites
Clindamycin
Anti-Bacterial Agents
Ribosomes
Lincosamides
Protein Synthesis Inhibitors
Cycloheximide
Proteins
Genes
Gels
Peptidyl Transferases
Plastids
Ribosomal RNA
Mitochondrial Genome
Plasmodium falciparum
Ribosomal DNA
Tetracycline

Keywords

  • Macrolides
  • Plastid
  • Protein synthesis
  • Ribosomes
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii : Implications for the target of macrolide antibiotics. / Beckers, Con J M; Roos, David S.; Donald, Robert G K; Luft, Benjamin J.; Schwab, J. Conrad; Cao, Yang; Joiner, Keith A.

In: Journal of Clinical Investigation, Vol. 95, No. 1, 01.1995, p. 367-376.

Research output: Contribution to journalArticle

Beckers, Con J M ; Roos, David S. ; Donald, Robert G K ; Luft, Benjamin J. ; Schwab, J. Conrad ; Cao, Yang ; Joiner, Keith A. / Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii : Implications for the target of macrolide antibiotics. In: Journal of Clinical Investigation. 1995 ; Vol. 95, No. 1. pp. 367-376.
@article{356e116c91bc48d5b2ba2c4062358d0b,
title = "Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii: Implications for the target of macrolide antibiotics",
abstract = "We investigated potential targets for the activity of protein synthesis inhibitors against the protozoan parasite Toxoplasma gondii. Although nanomolar concentrations of azithromycin and clindamycin prevent replication of T. gondii in both cell culture and in vivo assays, no inhibition of protein labeling was observed in either extracellular or intracellular parasites treated with up to 100 μM drug for up to 24 h. Quantitative analysis of > 300 individual spots on two-dimensional gels revealed no proteins selectively depleted by 100 μM azithromycin. In contrast, cycloheximide inhibited protein synthesis in a dose-dependent manner. Nucleotide sequence analysis of the peptidyl transferase region from genes encoding the large subunit of the parasite's ribosomal RNA predict that the cytoplasmic ribosomes of T. gondii, like other eukaryotic ribosomes, should be resistant to macrolide antibiotics. Combining cycloheximide treatment with two-dimensional gel analysis revealed a small subset of parasite proteins likely to be synthesized on mitochondrial ribosomes. Synthesis of these proteins was inhibited by 100 μM tetracycline, but not by 100 μM azithromycin or clindamycin. Ribosomal DNA sequences believed to be derived from the T. gondii mitochondrial genome predict macrolide/lincosamide resistance. PCR amplification of total T. gondii DNA identified an additional class of prokaryotic-type ribosomal genes, similar to the plastid-like ribosomal genes of the Plasmodium falciparum. Ribosomes encoded by these genes are predicted to be sensitive to the lincosamide/macrolide class of antibiotics, and may serve as the functional target for azithromycin, clindamycin, and other protein synthesis inhibitors in Toxoplasma and related parasites.",
keywords = "Macrolides, Plastid, Protein synthesis, Ribosomes, Toxoplasma gondii",
author = "Beckers, {Con J M} and Roos, {David S.} and Donald, {Robert G K} and Luft, {Benjamin J.} and Schwab, {J. Conrad} and Yang Cao and Joiner, {Keith A}",
year = "1995",
month = "1",
language = "English (US)",
volume = "95",
pages = "367--376",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii

T2 - Implications for the target of macrolide antibiotics

AU - Beckers, Con J M

AU - Roos, David S.

AU - Donald, Robert G K

AU - Luft, Benjamin J.

AU - Schwab, J. Conrad

AU - Cao, Yang

AU - Joiner, Keith A

PY - 1995/1

Y1 - 1995/1

N2 - We investigated potential targets for the activity of protein synthesis inhibitors against the protozoan parasite Toxoplasma gondii. Although nanomolar concentrations of azithromycin and clindamycin prevent replication of T. gondii in both cell culture and in vivo assays, no inhibition of protein labeling was observed in either extracellular or intracellular parasites treated with up to 100 μM drug for up to 24 h. Quantitative analysis of > 300 individual spots on two-dimensional gels revealed no proteins selectively depleted by 100 μM azithromycin. In contrast, cycloheximide inhibited protein synthesis in a dose-dependent manner. Nucleotide sequence analysis of the peptidyl transferase region from genes encoding the large subunit of the parasite's ribosomal RNA predict that the cytoplasmic ribosomes of T. gondii, like other eukaryotic ribosomes, should be resistant to macrolide antibiotics. Combining cycloheximide treatment with two-dimensional gel analysis revealed a small subset of parasite proteins likely to be synthesized on mitochondrial ribosomes. Synthesis of these proteins was inhibited by 100 μM tetracycline, but not by 100 μM azithromycin or clindamycin. Ribosomal DNA sequences believed to be derived from the T. gondii mitochondrial genome predict macrolide/lincosamide resistance. PCR amplification of total T. gondii DNA identified an additional class of prokaryotic-type ribosomal genes, similar to the plastid-like ribosomal genes of the Plasmodium falciparum. Ribosomes encoded by these genes are predicted to be sensitive to the lincosamide/macrolide class of antibiotics, and may serve as the functional target for azithromycin, clindamycin, and other protein synthesis inhibitors in Toxoplasma and related parasites.

AB - We investigated potential targets for the activity of protein synthesis inhibitors against the protozoan parasite Toxoplasma gondii. Although nanomolar concentrations of azithromycin and clindamycin prevent replication of T. gondii in both cell culture and in vivo assays, no inhibition of protein labeling was observed in either extracellular or intracellular parasites treated with up to 100 μM drug for up to 24 h. Quantitative analysis of > 300 individual spots on two-dimensional gels revealed no proteins selectively depleted by 100 μM azithromycin. In contrast, cycloheximide inhibited protein synthesis in a dose-dependent manner. Nucleotide sequence analysis of the peptidyl transferase region from genes encoding the large subunit of the parasite's ribosomal RNA predict that the cytoplasmic ribosomes of T. gondii, like other eukaryotic ribosomes, should be resistant to macrolide antibiotics. Combining cycloheximide treatment with two-dimensional gel analysis revealed a small subset of parasite proteins likely to be synthesized on mitochondrial ribosomes. Synthesis of these proteins was inhibited by 100 μM tetracycline, but not by 100 μM azithromycin or clindamycin. Ribosomal DNA sequences believed to be derived from the T. gondii mitochondrial genome predict macrolide/lincosamide resistance. PCR amplification of total T. gondii DNA identified an additional class of prokaryotic-type ribosomal genes, similar to the plastid-like ribosomal genes of the Plasmodium falciparum. Ribosomes encoded by these genes are predicted to be sensitive to the lincosamide/macrolide class of antibiotics, and may serve as the functional target for azithromycin, clindamycin, and other protein synthesis inhibitors in Toxoplasma and related parasites.

KW - Macrolides

KW - Plastid

KW - Protein synthesis

KW - Ribosomes

KW - Toxoplasma gondii

UR - http://www.scopus.com/inward/record.url?scp=0028832133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028832133&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 367

EP - 376

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -